2,6-Dimethyl-4-(1-methyl-butyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid bis-(3-pyridin-3-yl-propyl) ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2,6-Dimethyl-4-(1-methyl-butyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid bis-(3-pyridin-3-yl-propyl) ester
• 英文别名: Bis(3-pyridin-3-ylpropyl) 2,6-dimethyl-4-pentan-2-yl-1,4-dihydropyridine-3,5-dicarboxylate
• 化学式: C₃₀H₃₉N₃O₄
• 分子量: 505.657
• InChiKey: UBASVKBSHAHCHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  37
• 可旋转键数：
  15
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  90.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-吡啶丙醇 在 氨 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 反应 180.0h， 生成 2,6-Dimethyl-4-(1-methyl-butyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid bis-(3-pyridin-3-yl-propyl) ester
  参考文献：
  名称：

  Newly synthesized dihydropyridine derivatives as modulators of P-Glycoprotein-mediated multidrug resistance

  摘要：

  Newly synthesized 1,4-dihydropyridine derivatives possessing alkyl chains at the 4-position screened whether they could overcome P-glycoprotein-mediated multidrug resistance in cultured cancer cells and also leukemia-bearing animals. Of these derivatives, some could overcome drug resistance to doxorubicin and vincristine in multidrug resistant human cancer cell lines. Combined administration of vincristine and some of the derivatives significantly increased the life span of P-glycoprotein overexpressing multidrug-resistant P388 leukemia-bearing mice. The calcium antagonistic activities, an undesirable effects, were weaker than that of verapamil. These results suggested that the introduction of alkyl groups at the 4-position were effective for both overcoming multidrug resistance and reducing the calcium antagonistic activity. (C) 1998 Elsevier Science Ltd. Al rights reserved.

  DOI：

  10.1016/s0968-0896(98)00170-9

文献信息

• 1,4-DIHYDROPYRIDINE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME
  申请人：Nikken Chemicals Company, Limited

  公开号：EP0801065A1

  公开（公告）日：1997-10-15

  A 1,4-dihydropyridine compound having the formula (I): wherein, R1 indicates -COO-A-(3-pyridyl), A indicates a C3-C6 straight chain alkylene group in which one piperazine may be interposed; R2 indicates a C2-C10 alkyl group, alkenyl group or alkynyl group; a lower alkyl group or lower alkenyl group having a substituent; or a cycloalkyl group which may have a substituent; R3 indicates the same group as R1 or -COO-R4; and R4 indicates a lower alkyl group which may have a substituent or its pharmacologically acceptable salt and an anti-allergenic drug, antiphlogistic, drug for overcoming resistance to anti-cancer drugs, or drug for reinforcing the effect of anti-cancer drugs containing the same as effective ingredients.

  一种具有式（I）的 1，4-二氢吡啶化合物： 其中，R1 表示-COO-A-（3-吡啶基），A 表示 C3-C6 直链亚烷基，其中可插入一个哌嗪；R2 表示 C2-C10 烷基、烯基或炔基；具有取代基的低级烷基或低级烯基；或具有取代基的环烷基；R3 表示与 R1 相同的基团或-COO-R4；R4 表示可能具有取代基的低级烷基或其药理学上可接受的盐，以及作为有效成分的抗过敏药物、抗麻痹药物、克服抗癌药物抗药性的药物或增强抗癌药物效果的药物。
• Newly synthesized dihydropyridine derivatives as modulators of P-Glycoprotein-mediated multidrug resistance
  作者：Hirokazu Tanabe、Shigeyuki Tasaka、Hiromasa Ohmori、Noriaki Gomi、Yoshiyuki Sasaki、Toshiki Machida、Mayumi Iino、Akira Kiue、Seiji Naito、Michihiko Kuwano

  DOI：10.1016/s0968-0896(98)00170-9

  日期：1998.11

  Newly synthesized 1,4-dihydropyridine derivatives possessing alkyl chains at the 4-position screened whether they could overcome P-glycoprotein-mediated multidrug resistance in cultured cancer cells and also leukemia-bearing animals. Of these derivatives, some could overcome drug resistance to doxorubicin and vincristine in multidrug resistant human cancer cell lines. Combined administration of vincristine and some of the derivatives significantly increased the life span of P-glycoprotein overexpressing multidrug-resistant P388 leukemia-bearing mice. The calcium antagonistic activities, an undesirable effects, were weaker than that of verapamil. These results suggested that the introduction of alkyl groups at the 4-position were effective for both overcoming multidrug resistance and reducing the calcium antagonistic activity. (C) 1998 Elsevier Science Ltd. Al rights reserved.